Clinical perspectives on FINTEPLA® in Dravet syndrome: Insights from Prof Ingrid Scheffer and Prof Sameer Zuberi
|
Image
|
|
Laureate Professor Ingrid Scheffer AO Paediatric Neurologist and Epileptologist; Chair of Paediatric Neurology, Austin Health, University of Melbourne
MBBS, PhD, FRACP, FAES, FAHMS, FAA, FRS |
|
Image
|
|
Professor Sameer Zuberi Consultant Paediatric Neurologist, Royal Hospital for Children, Glasgow
MB ChB (Ed), MD, FRCP (Ed), FRCPCH |
FINTEPLA® Files
Laureate Professor Ingrid Scheffer AO
MBBS, PhD, FRACP, FAES, FAHMS, FAA, FRS
Paediatric Neurologist, Epileptologist
- Chair of Paediatric Neurology, Austin Health, The University of Melbourne
- Director of Paediatrics, Austin Health
- Honorary Senior Research Fellow, The Florey Institure of Neuroscience and Mental Health
- Honorary Research Fellow, Murdoch Children's Research Institute
Laureate Professor Ingrid Scheffer is a world-renowned Paediatric Neurologist and physician-scientist whose pioneering work in epilepsy genetics has transformed the field. Based at the University of Melbourne and the Florey Institute, she co-discovered the first epilepsy gene, advancing our understanding of the genetic basis of epilepsy. She also led a major revision of the International League Against Epilepsy’s classification system. Her contributions have earned her honours, including the Australian Prime Minister’s Prize for Science and election to the Royal Society (London).
Professor Sameer Zuberi
MB ChB (Ed), MD, FRCP (Ed), FRCPCH
- Consultant Paediatric Neurologist, Royal Hospital for Children, Glasgow
- Honorary Professor, School of Health and Wellbeing, and Lead, Paediatric Neurosciences Research Group, University of Glasgow
Professor Sameer Zuberi is a Consultant Paediatric Neurologist at the Royal Hospital for Children, Glasgow, and Honorary Professor at the University of Glasgow. He leads the Paediatric Neurosciences Research Group and is internationally recognised for advancing childhood epilepsy care and research. He heads the Scottish National Genetic Epilepsy Service and holds leadership roles across UK and European neurological organisations. His research focuses on genetics, precision therapies, and innovative technologies to improve outcomes and reduce SUDEP risk.
PBS Information: Authority required for Dravet syndrome. Not listed for Lennox-Gastaut syndrome. Refer to pbs.gov.au for further information.
Please review Product Information before prescribing FINTEPLA®. The full Product Information is available here.
▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.
WARNING: VALVULAR HEART DISEASE AND PULMONARY ARTERIAL HYPERTENSION
See Section 4.4 Special Warnings and Precautions for further detail.
There is an association between serotonergic drugs with 5-HT2B receptor agonist activity, including fenfluramine (the active ingredient in Fintepla®), and valvular heart disease and pulmonary arterial hypertension. Echocardiogram assessments are required before, during and after treatment with Fintepla®. Fintepla® is only available through a controlled access program.
AU-FA-2500111
Date of preparation: December 2025